Skip to main content
ORASURE TECHNOLOGIES INC logo

ORASURE TECHNOLOGIES INC — Investor Relations & Filings

Ticker · OSUR ISIN · US68554V1089 LEI · 529900GNNJPNM4XHXQ77 US Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2024-03-28 Director's Dealing
Country US United States of America
Listing US OSUR

About ORASURE TECHNOLOGIES INC

https://www.orasure.com/

OraSure Technologies, Inc. develops, manufactures, and distributes diagnostic products and sample collection tools. The company specializes in non-invasive technologies, particularly oral fluid-based solutions, to decentralize diagnostics and improve healthcare access. Its portfolio includes point-of-care and over-the-counter rapid tests for infectious diseases such as HIV and COVID-19. A notable achievement is the development of the first over-the-counter at-home HIV test. Through its subsidiaries, OraSure also provides sample management solutions for the collection of biological samples used in genomic, metabolomic, and microbiome research, serving healthcare providers, researchers, and consumers.

Recent filings

Filing Released Lang Actions
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-03-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and is clearly a proxy statement for the Annual Meeting of Stockholders of OraSure Technologies, Inc. It includes detailed information about proposals to be voted on at the Annual Meeting, including election of directors, ratification of auditors, executive compensation advisory vote, amendments to the Certificate of Incorporation, and stock award plan amendments. It also contains governance information, compensation discussion and analysis, and other proxy-related materials. The document is not an annual report, earnings release, or other financial report but is specifically a proxy solicitation document. According to the filing definitions, this matches the category 'Proxy Solicitation & Information Statement' (Code: PSI). The document length (15,000 characters) and content confirm it is the full proxy statement, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2024-03-22 English
Regulatory Filings 2024
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, but the content is not interpretable as a financial or corporate filing report.
2024-03-20 English
10-K
Annual Report FY 2023
2024-03-11 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-03-05 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-03-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.